Nanostics, an Edmonton-based precision health company, has secured funding from the University of Alberta Innovation Fund.

The funds will be used to increase the adoption of their ClarityDX Prostate® test in North America, enhancing diagnostic capabilities for prostate cancer.

Led by CEO Dr. John Lewis, Nanostics employs machine learning in its ClarityDX® platform to generate disease risk scores, improving diagnostic accuracy.

"This support will help us promote ClarityDX Prostate among men suspected of prostate cancer," said Dr. Lewis.